Investor Newsletter

Issue 01 2023

MicroPort®

MicroPort® Joins Singapore LIVE 2023

Singapore LIVE, the most important Singapore Interventional Cardiology event of the year, has been organized by the National Heart Centre of Singapore (NHCS) for over 30 years. MicroPort® recently participated in the Singapore LIVE 2023 conference presenting on a total solution for cardiovascular intervention, and held a satellite session on the topic of "How to optimize percutaneous coronary intervention (PCI) in complex lesions". This attracted extensive attention from experts and doctors.

Prof Yeo Khung Keong from NHCS was invited to join as the moderator for the symposium, and shared the 5-year outcomes of TARGET All Comers Randomized Trial of Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®) during the session. Dr. Anek Kanoksilp, Director of the Central Chest Institute of Thailand, also attended and presented a LM Bifurcation case treated by Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), emphasizing the proficiencies of Firehawk Liberty™, such as overexpansion capability and cell size.

With the success of Singapore LIVE 2023, MicroPort® was able to explore its presence in the Singaporean market with global experts, presenting the results of clinical studies and showcasing successful applications in complex lesions. In the future, MicroPort® will continue to pursue innovation with the most advanced products for a total Interventional Cardiology solution.

Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System Approved for Marketing in Russia

MicroPort® has recently received registration approval from the Federal Service for Surveillance in Healthcare of Russia for its self-developed Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™).

While retaining some features of previous Firehawk Stent, the new Firehawk Liberty™ uses an innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the crossability and vessel wall apposition.

Firehawk Liberty™ is currently approved in a number of countries and regions including the European Union, Korea, India, Brazil, Colombia, Belarus, Egypt, and Saudi Arabia. So far, MicroPort®'s line of drug-eluting stent products have been approved for use in 38 countries and regions around the world. The introduction of the Firehawk Liberty™ into the Russian market has further expanded MicroPort®'s range of coronary products available in the country. In the future, MicroPort® will continue to introduce more high-quality and innovative medical devices to overseas markets, so as to offer a more thorough medical solution for patients.

MicroPort

MicroPort® Coronary Balloon Catheters Receive Marketing Approval in Peru

MicroPort® has recently received marketing registration approval from the Peruvian General Directorate of Medicines, Supplies and Drugs for its self-developed coronary balloon catheters, the Foxtrot™ Pro Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter, the Foxtrot™ NC PTCA Balloon Catheter, the Firefighter™ PTCA Balloon Catheter, and the Firefighter™ NC Balloon Catheter.

The Firehawk® Rapamycin Target Eluting Coronary Stent System and the Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System entered the Peruvian market in 2014 and 2022, respectively. The recent approval of multiple balloon dilatation catheters has further enriched the coronary intervention portfolio of MicroPort® in Peru and will contribute to providing an integrated solution for physicians. In the future, MicroPort® will continue to strengthen its efforts in developing the Peruvian market and make more high-quality products available in Peru for the benefit of patients and medical professionals.

Foxtrot™ NC PTCA Balloon Catheter

MicroPort® Coronary Foxtrot™ NC Balloon Catheter Approved for Sale in Indonesia

MicroPort® has been granted a registration certificate by the Ministry of Health of the Republic of Indonesia for its independently developed Foxtrot™ NC PTCA Balloon Catheter.

The Foxtrot™ NC PTCA Balloon Catheter is a non-compliant rapid-exchange balloon catheter indicated for coronary artery balloon angioplasty. By assisting in the implantation of balloon stents, it can improve the result of myocardial perfusion scans. The distal tip of the catheter is equipped with a non-compliant balloon that inflates to the rated diameter and length at recommended pressures. Two radiopaque markers on the balloon allow intraoperative X-ray fluoroscopy to monitor its location in the body.

As a significant hub along the "Belt and Road," in recent years, Indonesia has seen a sharp increase in the market size of medical devices, particularly in the substantial growth in demand for cardiovascular therapy products. Prior to this, a number of other medical devices for cardiovascular intervention entered the Indonesian market, including the Firehawk® Rapamycin Target Eluting Coronary Stent System, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System and Foxtrot Pro™ PTCA Balloon Catheter. These were well-received by patients and medical professionals for their exceptional product features and clinical performance.

MicroPort

Endovastec™ Minos® Abdominal Aortic Stent-Graft and Delivery System Receives Approval for Marketing in South Korea

Endovastec™ has received registration approval from the Ministry of Food and Drug Safety of Korea (MFDS) for its independently developed Minos® Abdominal Aortic Stent-Graft and Delivery System (Minos® Stent Graft System). This is the first time the Minos® Stent Graft System has received marketing approval in an overseas market in Asia. The Minos® Stent Graft System was approved for marketing in China in 2019 and received the CE marking in the same year. Since its approval, the Minos® Stent Graft System has been available in 14 markets, including China, Greece, the United Kingdom, Poland, Germany, Brazil, and Argentina.

South Korea is a major importer of medical devices in Asia and the market for these products has been growing rapidly in recent years. It is currently one of the top four markets in Asia in terms of market size. In early August 2022, Endovastec™ successfully passed the review process administered by MFDS and obtained the Korea Medical Device Quality System (KGMP) certification, paving the way for its products to access the Korean market. The approval of the Minos® Stent Graft System in South Korea is an important first step for Endovastec™ to enter the Korean market. It is expected to provide a solid boost to Endovastec™'s efforts to further develop its presence in the Asian market and broaden its global reach.

Endovastec™ Completes First Pre-market Clinical Implantation of TIPS Stent Graft System

Intervastec™, a subsidiary of Endovastec™, has officially launched a clinical study of its independently developed Transjugular Intrahepatic Portosystemic Shunt (TIPS) Stent Graft System at Zhongshan Hospital of Fudan University (Zhongshan Hospital). The clinical study will be led by its principal investigator Zhiping Yan, who is the Director of the Department of Interventional Therapies at Zhongshan Hospital. Recently, the first pre-market clinical implantation of the TIPS Stent Graft System was successfully completed in Rui'an People's Hospital by Prof. Changsheng Shi and his interventional vascular surgery team.

As the first product independently developed by Intervastec™ for treatment of portal hypertension and its complications, the TIPS Stent Graft System is expected to benefit more portal hypertension patients after its domestic launch. The TIPS Stent Graft System adopts the design of a covered cut stent combined with woven stent, providing good radial support and flexibility to maintain good stent shape and patency. At the same time, the use of a cut stent can improve blood flow and enhance the bypass effect of the stent. The method of pulling the outer sheath through joint shaft rotation on the conveyor to release the stent can ensure smoothness and convenience of the stent release process as well as precise stent positioning.

Founded in 2021 by Endovastec™, Intervastec™ is dedicated to the research and development of oncology interventional medical devices. Currently, in addition to the TIPS Stent Graft System, it has a number of innovative products in development. In the future, Intervastec™ will continue to launch more high-quality innovative products, continuously improve the composition of its product lines, enhance its competitiveness in the oncology interventional medical devices market, and benefit oncology patients worldwide.

MicroPort

MicroPort® MedBot® Performs World's First Robotic Positioned Cryoablation of Prostate Cancer

The world's first prostate cancer focal treatment using a prostate positioning robot in combination with the cryoablation platform was successfully completed by Professor Hongqian Guo's team from the Department of Urology of Gulou Hospital, affiliated with Nanjing University School of Medicine (Gulou Hospital). The Mona Lisa Robotic Prostate Puncture System (Mona Lisa) developed by Shanghai Intbot, together with the cryoablation device developed by AccuTarget MediPharma assists in preserving the patient's prostate gland by increasing positioning precision of the surgical operation and decreasing risk of damage. The success of this case marks the clinical validation of precise therapy by the Mona Lisa in the field of percutaneous puncture, opening up a new horizon for the development of precise and minimally invasive prostate treatment procedures, which is expected to provide more solutions for patients.

According to Mr. Yu Liu, Chief Commercial Officer of MicroPort® MedBot®: "This surgery combined the Mona Lisa Prostate Puncture and Positioning device with a cryoablation device. As a less invasive treatment method, it turns cutting-edge scientific research into clinical application. It is also a new breakthrough for the Mona Lisa in the field of percutaneous puncture. MicroPort® MedBot® will continue to invest more in R&D and clinical studies, deepen medical-industrial cooperation, as well as optimize product performance and surgical solutions through clinical communication and exploration. We are committed to providing more minimally invasive, intelligent and precise robotic technology to benefit more patients and realize our aspiration from day one to eliminate difficult surgeries in the world."

MicroPort

Horizon Medical™'s Daylily® Embryo Transfer Catheter Obtains FDA 510(k) Approval

The Daylily® Embryo Transfer Catheter, independently developed by HorizonMedical™, successfully received Food and Drug Administration (FDA) 510(k) approval, becoming the first HorizonMedical™ product to obtain approval in the United States of America (U.S.).

The Daylily® Embryo Transfer Catheter is used in embryo transfer procedures, allowing doctors to gently implant in vitro embryos into the uterine cavity via the cervix relatively quickly. The catheter's design comprises a smooth tip, which can effectively reduce irritation to the uterus, and a highly flexible guide, which is easy to manipulate. The addition of a matching stylet offers an effective solution to anteflexion and retroflexion embryo transfer.

Dr. Zong Guo, Executive Vice President of HorizonMedical™ has stated: "The Daylily® Embryo Transfer Catheter was registered and approved in China in 2020 and in Thailand in 2021, and has received recognition by experts in clinical applications. The FDA 510(K) marketing approval is a milestone for HorizonMedical™ to grow in the U.S. market. In the future, Horizon Medical™ will further improve its product portfolio and accelerate its market expansion both domestically and globally."

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com